Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Immunoglobulin Light-chain Amyloidosis 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

Carboplatin 339 Cisplatin 238 Paclitaxel 203 Radiotherapy 194 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 140 Erlotinib Hydrochloride 107 Etoposide 98 Magnetic Resonance Spectroscopy 92 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 71 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 Irinotecan 42 atezolizumab 41 Topotecan 39 Radiation 39 Biopsy 39 Cyclophosphamide 38 Standard of Care 37 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Biological Assay × Clear all

NCT06716580 2025-12-10

EQUAL

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡